VERINURAD

Details

Stereochemistry	ACHIRAL
Molecular Formula	C20H16N2O2S
Molecular Weight	348.418
Optical Activity	NONE
Defined Stereocenters	0 / 0
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

CC(C)(SC1=C(C=NC=C1)C2=C3C=CC=CC3=C(C=C2)C#N)C(O)=O

InChI

InChIKey=YYBOLPLTQDKXPM-UHFFFAOYSA-N

InChI=1S/C20H16N2O2S/c1-20(2,19(23)24)25-18-9-10-22-12-17(18)16-8-7-13(11-21)14-5-3-4-6-15(14)16/h3-10,12H,1-2H3,(H,23,24)

HIDE SMILES / InChI

Molecular Formula	C20H16N2O2S
Molecular Weight	348.418
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/28386072 | https://www.ncbi.nlm.nih.gov/pubmed/28744099 | https://www.ncbi.nlm.nih.gov/pubmed/29868853

Verinurad (RDEA3170) is a selective uric acid reabsorption inhibitor in clinical development for the treatment of gout and asymptomatic hyperuricemia. Verinurad specifically inhibits URAT1 with a potency of 25 nM. High affinity inhibition of uric acid transport requires URAT1 residues Cys-32, Ser-35, Phe-365 and Ile-481. Unlike other available uricosuric agents, the requirement for Cys-32 is unique to verinurad. Verinurad doses as low as 2.5 mg produce significant sUA lowering in humans, and this greater reduction in sUA may lead to improved outcomes and medical benefits for patients with gout. Verinurad in monotherapy studies has been associated with increased urinary uric acid concentrations and low rates of serum creatinine (sCr) elevation. Verinurad combined with febuxostat decreased sUA dose-dependently while maintaining uric acid excretion similar to baseline. All dose combinations of verinurad and febuxostat were generally well tolerated.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Solute carrier family 22 member 12 10 Target ID: CHEMBL6120 Sources: https://www.ncbi.nlm.nih.gov/pubmed/28386072	Inhibitor 8297		25.0 nM [IC50]

PubMed

Title	Date	PubMed
Pharmacodynamic and pharmacokinetic effects and safety of verinurad in combination with febuxostat in adults with gout: a phase IIa, open-label study.	2018	29657831
Effect of Renal Impairment on the Pharmacokinetics and Pharmacodynamics of Verinurad, a Selective Uric Acid Reabsorption Inhibitor.	2018 Aug	29949102
Verinurad combined with febuxostat in Japanese adults with gout or asymptomatic hyperuricaemia: a phase 2a, open-label study.	2018 Sep 1	29868853

Sample Use Guides

In Vivo Use Guide

Panels of eight male subjects received a single oral dose of verinurad or placebo in either a fasted or fed state; panels of 10-12 male subjects received ascending doses of once-daily verinurad or placebo in a fasted state for 10 days. Verinurad reduced serum urate levels by up to 62% (40 mg, single dose) and 61% (10 mg, multiple dose). The increase in urinary excretion of uric acid was greatest in the first 6 hours after dosing and was still evident ≥24 hours for verinurad doses ≥2 mg. Verinurad was well tolerated at all doses.

Route of Administration: Oral

In Vitro Use Guide

Verinurad specifically inhibits URAT1 with a potency of 25 nM.

Substance Class	Chemical Created by `admin` on `Sat Dec 16 07:56:45 GMT 2023` Edited by `admin` on `Sat Dec 16 07:56:45 GMT 2023`
Record UNII	12WJ62D047
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

VERINURAD

Official Name

English

Verinurad [WHO-DD]

Common Name

English

verinurad [INN]

Common Name

English

VERINURAD [USAN]

Common Name

English

PROPANOIC ACID, 2-((3-(4-CYANO-1-NAPHTHALENYL)-4-PYRIDINYL)THIO)-2-METHYL-

Systematic Name

English

RDEA-3170

Code

English

RDEA3170

Code

English

Classification Tree Code System Code

NCI_THESAURUS

C921